Business Context and Reporting Period
Imunon, Inc. (IMNN) filed a Current Report on Form 8-K on June 1, 2026, regarding a material definitive agreement entered into on June 2, 2026, and closed on June 3, 2026. The transaction involves a financing arrangement with Streeterville Capital, LLC, designed to provide capital for general corporate purposes, including research and development, capital expenditures, and working capital.
Key Financial Metrics and Transaction Structure
The transaction resulted in the following capital structure and cash flows:
- Total Proceeds: $10,000,000 received at closing.
- Preferred Stock: Issuance of 250 shares of Series A Preferred Stock at $10,000 per share ($2,500,000 aggregate).
- Debt Instruments:
- Secured Promissory Note A-1: $2,720,000 principal; 8% annual interest; 18-month maturity.
- Secured Promissory Note B: $5,000,000 principal; 5% annual interest; 18-month maturity.
- Cash Collateral: $5,000,000 of the proceeds was deposited into a restricted Cash Collateral Account to secure the Notes.
- Available Liquidity: $5,000,000 available for immediate use, subject to release of collateral upon specific debt reduction milestones.
- Transaction Costs: Placement agent fee of 7.0% of gross proceeds ($700,000).
Material Changes and Terms
The filing details significant changes to the company's capital structure and obligations:
- Collateralization: The Notes are secured by substantially all company assets excluding intellectual property, with guarantees from certain subsidiaries.
- Redemption Rights:
- Investor Rights: Beginning six months post-closing, the investor may redeem up to $250,000 of the A-1 Note monthly. Additional redemption rights exist if the common stock trades 15% above the Nasdaq "Minimum Price."
- Company Rights: The company may redeem Series A Preferred Stock at 110% of the liquidation amount.
- Prepayment Penalties: Prepayment of Notes incurs a 10% premium on principal amounts prepaid.
- Default Consequences: Upon an event of default, interest rates on Notes increase to the lesser of 15% or the maximum legal rate. The Preferred Return increases by 15% per year for up to three separate default events.
- Note Exchange Mechanism: If the A-1 Note or Preferred Shares are reduced by $2,000,000, the company may exchange up to $1,000,000 of the B Note for a new A-1 Note, releasing corresponding cash from the Collateral Account.
Outlook, Risks, and Management Commentary
Management intends to utilize the unrestricted $5,000,000 proceeds for research and development, capital expenditures, and working capital. The filing highlights several material risks:
- Liquidity Constraints: Half of the raised capital is restricted in a collateral account until specific debt reduction thresholds are met.
- Financial Covenants: The company is subject to customary covenants; failure to comply could trigger acceleration of debt obligations.
- Cost of Capital: The financing carries significant interest costs (5-8% base, up to 15% on default) and a 10% prepayment penalty, increasing the effective cost of capital.
- Equity Dilution: While the Preferred Stock is not convertible to common stock, it accrues an 8% return payable in cash or additional preferred shares, potentially increasing the preferred equity burden.
Investor Verification Checklist
- Verify the exact amount of unrestricted cash available for operations after deducting the 7% placement fee ($700,000) from the $5,000,000 unrestricted portion.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) to understand specific financial covenants and events of default.
- Confirm the current trading price of IMNN common stock relative to the Nasdaq "Minimum Price" to assess the risk of accelerated investor redemption.
- Assess the company's ability to service the $7,720,000 in total debt principal and associated interest payments within the 18-month maturity window.
- Examine the Certificate of Designation (Exhibit 3.1) for details on the liquidation preference and redemption mechanics of the Series A Preferred Stock.